NCT00343044View on ClinicalTrials.gov

Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

January 31, 2010

Study Completion Date

August 31, 2011

Conditions
Ovarian CancerFallopian Tube CancerPeritoneal Cancer
Interventions
DRUG

Topotecan

Topotecan administered days 1, 8, and 15 of each 28 day cycle. Dose was 4 mg/m2 administered IV.

DRUG

Bevacizumab

bevacizumab administered IV 10 mg/kg, days 1 and 15 of 28 day cycle.

Trial Locations (2)

98101

Virginia Mason Medical Center, Seattle

98104

Puget Sound Oncology Consortium (PSOC), Seattle

Sponsors
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

Benaroya Research Institute

OTHER